Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
G protein-coupled receptors (GPCRs) play key roles in a variety of physiologic functions. Additionally we are shipping LGR4 Kits (17) and LGR4 Proteins (7) and many more products for this protein.
Showing 10 out of 90 products:
Human Monoclonal LGR4 Primary Antibody for cELISA, FACS - ABIN1720913
Loh, Broussard, Liu, Copeland, Gilbert, Jenkins, Kolakowski: Chromosomal localization of GPR48, a novel glycoprotein hormone receptor like GPCR, in human and mouse with radiation hybrid and interspecific backcross mapping. in Cytogenetics and cell genetics 2000
Show all 3 references for 1720913
Human Monoclonal LGR4 Primary Antibody for cELISA, FACS - ABIN1381741
Loh, Broussard, Kolakowski: Molecular characterization of a novel glycoprotein hormone G-protein-coupled receptor. in Biochemical and biophysical research communications 2001
Show all 2 references for 1381741
Human Polyclonal LGR4 Primary Antibody for IHC, IHC (p) - ABIN4330846
Steffen, Simon, Warneke, Balschun, Ebert, Röcken: LGR4 and LGR6 are differentially expressed and of putative tumor biological significance in gastric carcinoma. in Virchows Archiv : an international journal of pathology 2012
Human Polyclonal LGR4 Primary Antibody for IHC (p) - ABIN4330842
Shannon: IQGAP Family Members in Yeast, Dictyostelium, and Mammalian Cells. in International journal of cell biology 2012
Data (including data from studies using transgenic/knockout mice) suggest that LGR4 is key protein necessary for prostate cancer epithelial-mesenchymal transition and metastasis; LGR4 expression is elevated in human prostate cancer cell lines with metastatic potential; LGR4 silencing in prostate cancer cell line impairs cell migration and invasion without affecting cell proliferation.
LGR4 is another receptor for RANKL (show TNFSF11 Antibodies). LGR4 competes with RANK to bind RANKL (show TNFSF11 Antibodies) and suppresses canonical RANK signaling during osteoclast differentiation.
The LGR4 A750T variant is correlated with central obesity-related characteristics in young subjects.
Lgr4 is a critical positive factor for skin tumorigenesis by mediating the activation of MEK1 (show MAP2K1 Antibodies)/ERK1/2 (show MAPK1/3 Antibodies) and Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) pathways.
miR (show MLXIP Antibodies)-34a gene expression upregulation inhibits ARPE-19 cell proliferation, migration and adhesion partly by suppressing LGR4 expression.
Lgr4 activates Jmjd2a (show KDM4A Antibodies)/AR signaling pathway to promote interaction AR with PSA (show PLAG1 Antibodies) promoter, causing reduction of prostate cancer apoptosis and cell cycle arrest.
A mechanistic understanding of RANKL (show TNFSF11 Antibodies)-LGR4 interaction has provided new insight into LGR4 mediated RANKL (show TNFSF11 Antibodies) signaling in osteoporosis and other diseases
miR (show MLXIP Antibodies)-218 directly targets LGR4 and modulated the PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) and Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) pathways in the LNCaP-IL-6 (show IL6 Antibodies)+ cells.
LGR4 promotes tumorigenesis of prostate cancer via PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies) signaling pathway.
These findings suggest that aberrant RSPO3 (show RSPO3 Antibodies)-LGR4 signaling potentially acts as a driving mechanism in the aggressiveness of Keap1 (show KEAP1 Antibodies)-deficient lung ADs (show AGPS Antibodies).
LGR4 is another receptor for RANKL (show TNFSF11 Antibodies). LGR4 competes with RANK to bind RANKL (show TNFSF11 Antibodies) and suppresses canonical RANK signaling during osteoclast differentiation. Both whole-body (Lgr4(-/-)) and monocyte conditional knockout mice of Lgr4 (Lgr4 CKO) exhibit osteoclast hyperactivation (including elevation of osteoclast number, surface area, and size) and increased bone erosion.
RSPO (show RSPO1 Antibodies)-LGR4/5-ZNRF3 (show ZNRF3 Antibodies)/RNF43 (show RNF43 Antibodies) module controls metabolic liver zonation and is a hepatic growth/size rheostat during development, homeostasis and regeneration.
These date indicate that hydrogen peroxide suppresses Lgr4 expression in osteoblastic cells.
Lgr4 gene is regulated by BMP and is required for BMP effects on osteoblastic differentiation.
Rspo1 (show RSPO1 Antibodies) and its receptor of leucine-rich repeat containing G-protein-coupled receptor 4 (Lgr4) should be a novel molecular signal in the transmission of mechanical stimuli to biological signal in the bone, and this signal should be in the upstream of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling for bone formation.
Study suggests that miR (show MLXIP Antibodies)-34c contributes to osteoclast differentiation by targeting LGR4, providing novel insights into understanding the molecular mechanism underlying osteoclast differentiation.
LGR4 acted as a key receptor for Rspo2 (show RSPO2 Antibodies) to promote osteogenesis.
G protein-coupled receptors (GPCRs) play key roles in a variety of physiologic functions. Members of the leucine-rich GPCR (LGR) family, such as GPR48, have multiple N-terminal leucine-rich repeats (LRRs) and a 7-transmembrane domain (Weng et al., 2008
G protein-coupled receptor 48
, leucine-rich repeat-containing G-protein coupled receptor 4
, G protein-coupled receptor GPR48
, G-protein coupled receptor 48